Skip to main content
Premium Trial:

Request an Annual Quote

Miragen Closes $20M Series B Financing

Premium

Miragen Therapeutics this week announced that it has closed a $20 million Series B round of financing.

The financing was led by Remeditex Ventures with participation from Miragen's existing investor base, including Atlas Venture, Boulder Ventures, Amgen Ventures, and Broadview Ventures.

The company said the funding would be used to advance its pipeline of microRNA-based drugs.

The Scan

Highly Similar

Researchers have uncovered bat viruses that are highly similar to SARS-CoV-2, according to Nature News.

Gain of Oversight

According to the Wall Street Journal, the Biden Administration is considering greater oversight of gain-of-function research.

Lasker for mRNA Vaccine Work

The Scientist reports that researchers whose work enabled the development of mRNA-based vaccines are among this year's Lasker Award winners

PLOS Papers on Causal Variant Mapping, Ancient Salmonella, ALK Fusion Test for NSCLC

In PLOS this week: MsCAVIAR approach to map causal variants, analysis of ancient Salmonella, and more.